SCHEMBL22062402

SCHEMBL22062402

CC[C@@H]1CN(C[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)C[C@H](n2cnc3c(N)ncnc32)O1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 3/20 0.60
ADORA3 P0DMS8 2/20 0.60
DPP4 P27487 1/20 0.60
MEN1 O00255 1/20 0.60
SLC28A1 O00337 1/20 0.60
MAP3K7 O43318 1/20 0.60
SLC28A2 O43868 1/20 0.60
GAPDH P04406 1/20 0.60
MAPK1 P28482 1/20 0.60
ADORA2A P29274 1/20 0.60
ADORA2B P29275 1/20 0.60
ADORA1 P30542 1/20 0.60
STAT6 P42226 1/20 0.60
PI4KA P42356 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PI4K2B Q8TCG2 1/20 0.60
SLC29A1 Q99808 1/20 0.60
PI4K2A Q9BTU6 1/20 0.60
SLC28A3 Q9HAS3 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25634790 0.90 EHMT1 (0.59) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL22110013 0.90 EHMT1 (0.59) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL22062401 0.90 EHMT1 (0.59) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL19760484 0.90 EHMT1 (0.59) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL25634757 0.85 DOT1L (0.69) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL173151 0.83 DPP4 (0.74) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL59610 0.83 DPP4 (0.74) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL13986299 0.83 DPP4 (0.74) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL18430888 0.82 DOT1L (0.80) DOT1LADORA3DPP4MEN1SLC28A1
SCHEMBL21160482 0.82 DOT1L (0.80) DOT1LADORA3DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 US disclosed
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2020-06-18 US disclosed
US-10676499-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA NOVARTIS AG (CH) 2020-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 DOT1L 1171/4885ADORA3 645/4885DPP4 1655/4885
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 DOT1L 1171/4885ADORA3 645/4885DPP4 1655/4885
US-10676499-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA RNGTT, NSUN3, NSUN2 DOT1L 1103/4885ADORA3 553/4885DPP4 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.